nimbolide has been researched along with 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arunakaran, J; Arunkumar, R; Benson, CS; Elumalai, P; Sharmila, G | 1 |
1 other study(ies) available for nimbolide and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
Nimbolide inhibits IGF-I-mediated PI3K/Akt and MAPK signalling in human breast cancer cell lines (MCF-7 and MDA-MB-231).
Topics: beta Catenin; Breast Neoplasms; Cell Line, Tumor; Chromones; Down-Regulation; Female; G1 Phase Cell Cycle Checkpoints; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Limonins; MCF-7 Cells; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; PTEN Phosphohydrolase; Receptor, IGF Type 1; Signal Transduction | 2014 |